Provectus Biopharmaceuticals Inc (OTCMKTS:PVCT) made an announcement on August 24, 2022, that it has expanded its sponsored research program with Michio Kurosu, PhD, Professor, Department of Pharmaceutical Sciences at the College of Pharmacy of the University of Tennessee Health Science Center (UTHSC) in Memphis, Tennessee.
Trading Data
On Wednesday, PVCT stock fell 3.86% to $0.0510 with more than 508.01K shares, compared to volume of 153.82K shares. The stock moved within a range of $0.0500 – 0.0542 after opening trade at $0.0503.
Provectus Biopharmaceuticals Expands Sponsored Research Collaboration with University of Tennessee Health Science Center to Investigate Pharmaceutical-Grade Rose Bengal as Anti-Fungal and Anti-Oral Bacterial Agent
The program has been expanded for the purpose of investigating Provectus’ pharmaceutical-grade rose bengal for the treatment of anti-fungal and anti-oral bacterial infections. The company’s innovatively assembled and proprietary rose bengal is the lead member of a class of its small molecules called halogenated xanthenes.
Provectus Biopharmaceuticals Expands Sponsored Research Collaboration with University of Calgary (Canada) to Investigate Systemic Administration of Pharmaceutical-Grade Rose Bengal for Treatment of Pediatric Leukemia
On August 17, 2022, Provectus announced the expansion of another sponsored research program with Aru Narendran, MD, PhD, Professor, Departments of Pediatrics, Oncology, Biochemistry & Molecular Biology, and Physiology & Pharmacology at the Cumming School of Medicine of the University of Calgary in Calgary, Alberta, Canada. The reason was to investigate systemic administration of Provectus’ pharmaceutical-grade rose bengal for the treatment of pediatric leukemia.
The Kurosu team plans to evaluate the in vitro activity of Provectus’ rose bengal against different fungal strains and to conduct susceptibility tests against fungal and bacterial mouth microbes. On the other hand, the Narendran team plans to identify clinically-feasible drug combinations and synthetic lethality that have synergistic activity with Provectus’ rose Bengal, apart from a bunch of other goal-oriented initiatives.
Technical Data
PVCT stock is below the 20-Day and 50-Day Moving averages of $0.0545 and $0.0570 respectively. Moreover, the stock is trading below the 200-Day moving average of $0.0596. The stock is down 25% over the past 6 months.
